These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 34744992)

  • 1. Case Report: Multiple Sclerosis Relapses After Vaccination Against SARS-CoV2: A Series of Clinical Cases.
    Nistri R; Barbuti E; Rinaldi V; Tufano L; Pozzilli V; Ianniello A; Marinelli F; De Luca G; Prosperini L; Tomassini V; Pozzilli C
    Front Neurol; 2021; 12():765954. PubMed ID: 34744992
    [No Abstract]   [Full Text] [Related]  

  • 2. The Safety Profile of Common COVID-19 Vaccines in Patients With Multiple Sclerosis.
    Aladdin YS; Alqarni DA; Alamoudi SW; Alharbi AA; Fudhah WA; Alghamdi G; Attar A
    Cureus; 2024 Feb; 16(2):e54852. PubMed ID: 38533153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of Relapse After COVID-19 Vaccination Among Patients With Multiple Sclerosis in France: A Self-Controlled Case Series.
    Moisset X; Leray E; Chenaf C; Taithe F; Vukusic S; Mulliez A; Clavelou P
    Neurology; 2024 Sep; 103(5):e209662. PubMed ID: 39141880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New relapse of multiple sclerosis and neuromyelitis optica as a potential adverse event of AstraZeneca AZD1222 vaccination for COVID-19.
    Fragoso YD; Gomes S; Gonçalves MVM; Mendes Junior E; Oliveira BES; Rocha CF; Santos GACD; Tauil CB; Araujo RV; Peron JPS
    Mult Scler Relat Disord; 2022 Jan; 57():103321. PubMed ID: 35158439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Case of Acute Pulmonary Embolus after mRNA SARS-CoV-2 Immunization.
    Wiest NE; Johns GS; Edwards E
    Vaccines (Basel); 2021 Aug; 9(8):. PubMed ID: 34452028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case Report: Exacerbation of Relapses Following mRNA COVID-19 Vaccination in Multiple Sclerosis: A Case Series.
    Quintanilla-Bordás C; Gascón-Gimenez F; Alcalá C; Payá M; Mallada J; Silla R; Carratalà-Boscà S; Gasque-Rubio R; Castillo J; Casanova B
    Front Neurol; 2022; 13():897275. PubMed ID: 35572939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency and Characteristics of Nodal and Deltoid FDG and
    Schroeder DG; Jang S; Johnson DR; Takahashi H; Navin PJ; Broski SM; Thorpe MP; Johnson GB; Young JR
    AJR Am J Roentgenol; 2021 Nov; 217(5):1206-1216. PubMed ID: 34009000
    [No Abstract]   [Full Text] [Related]  

  • 9. Retinal Vascular Events after mRNA and Adenoviral-Vectored COVID-19 Vaccines-A Case Series.
    Girbardt C; Busch C; Al-Sheikh M; Gunzinger JM; Invernizzi A; Xhepa A; Unterlauft JD; Rehak M
    Vaccines (Basel); 2021 Nov; 9(11):. PubMed ID: 34835280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021.
    Achiron A; Dolev M; Menascu S; Zohar DN; Dreyer-Alster S; Miron S; Shirbint E; Magalashvili D; Flechter S; Givon U; Guber D; Stern Y; Polliack M; Falb R; Gurevich M
    Mult Scler; 2021 May; 27(6):864-870. PubMed ID: 33856242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies - the Polish experience.
    Czarnowska A; Brola W; Zajkowska O; Rusek S; Adamczyk-Sowa M; Kubicka-Bączyk K; Kalinowska-Łyszczarz A; Kania K; Słowik A; Wnuk M; Marona M; Podlecka-Piętowska A; Nojszewska M; Zakrzewska-Pniewska B; Jasińska E; Gołuch K; Lech B; Noga M; Perenc A; Popiel M; Lasek-Bal A; Puz P; Maciejowska K; Kucharska-Lipowska M; Lipowski M; Kapica-Topczewska K; Chorąży M; Tarasiuk J; Kochanowicz J; Kulikowska J; Wawrzyniak S; Niezgodzińska-Maciejek A; Pokryszko-Dragan A; Gruszka E; Budrewicz S; Białek M; Kurkowska-Jastrzębska I; Kurowska K; Stępień A; Włodek A; Ptasznik V; Pawełczyk M; Sobolewski P; Lejmel H; Strzalińska K; Maciejowski M; Tutaj A; Zwiernik J; Litwin A; Lewańczyk B; Paprocka I; Zwiernik B; Pawlos A; Borysowicz A; Narożnik A; Michałowska A; Nosek K; Fudala M; Milewska-Jędrzejczak M; Kułakowska A; Bartosik-Psujek H
    Neurol Neurochir Pol; 2021; 55(2):212-222. PubMed ID: 33856686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple sclerosis relapse after COVID-19 vaccination: A case report-based systematic review.
    Nabizadeh F; Ramezannezhad E; Kazemzadeh K; Khalili E; Ghaffary EM; Mirmosayyeb O
    J Clin Neurosci; 2022 Oct; 104():118-125. PubMed ID: 36029752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.
    Rosenblum HG; Hadler SC; Moulia D; Shimabukuro TT; Su JR; Tepper NK; Ess KC; Woo EJ; Mba-Jonas A; Alimchandani M; Nair N; Klein NP; Hanson KE; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Mbaeyi SA; Oliver SE
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(32):1094-1099. PubMed ID: 34383735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021.
    See I; Su JR; Lale A; Woo EJ; Guh AY; Shimabukuro TT; Streiff MB; Rao AK; Wheeler AP; Beavers SF; Durbin AP; Edwards K; Miller E; Harrington TA; Mba-Jonas A; Nair N; Nguyen DT; Talaat KR; Urrutia VC; Walker SC; Creech CB; Clark TA; DeStefano F; Broder KR
    JAMA; 2021 Jun; 325(24):2448-2456. PubMed ID: 33929487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy.
    Bowen J; Mehta R; Pelletier C; Tian M; Noxon V; Johnson BH; Bonafede M
    Adv Ther; 2020 Jul; 37(7):3163-3177. PubMed ID: 32436028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of Allergic Reactions After Pfizer-BioNTech COVID-19 Vaccination Among Adults With High Allergy Risk.
    Shavit R; Maoz-Segal R; Iancovici-Kidon M; Offengenden I; Haj Yahia S; Machnes Maayan D; Lifshitz-Tunitsky Y; Niznik S; Frizinsky S; Deutch M; Elbaz E; Genaim H; Rahav G; Levy I; Belkin A; Regev-Yochay G; Afek A; Agmon-Levin N
    JAMA Netw Open; 2021 Aug; 4(8):e2122255. PubMed ID: 34463744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Humoral Response Induced by Prime-Boost Vaccination with the ChAdOx1 nCoV-19 and mRNA BNT162b2 Vaccines in a Teriflunomide-Treated Multiple Sclerosis Patient.
    Michiels Y; Houhou-Fidouh N; Collin G; Berger J; Kohli E
    Vaccines (Basel); 2021 Oct; 9(10):. PubMed ID: 34696248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment Patterns and Relapses Among Newly Treated Multiple Sclerosis Patients From a Retrospective Claims Analysis.
    Kantor D; Mehta R; Pelletier C; Tian M; Noxon V; Johnson BH; Bonafede M
    Clin Ther; 2020 Nov; 42(11):2136-2147.e3. PubMed ID: 33160682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ¿ Can COVID-19 exacerbate multiple sclerosis symptoms? A case series analysis.
    Michelena G; Casas M; Eizaguirre MB; Pita MC; Cohen L; Alonso R; Garcea O; Silva BA
    Mult Scler Relat Disord; 2022 Jan; 57():103368. PubMed ID: 35158474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fine needle aspiration in COVID-19 vaccine-associated lymphadenopathy.
    Hagen C; Nowack M; Messerli M; Saro F; Mangold F; Bode PK
    Swiss Med Wkly; 2021 Jul; 151():w20557. PubMed ID: 34286849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.